Cargando…
Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7)
[Image: see text] Introduction: Breast cancer is the most serious cause of women’s death throughout the world. Using nanocarrier vehicles to the exact site of cancer upgrades the therapeutic efficiency of the drugs. Capsulation of active proteins in the vesicular liposomes’ hydrophilic core is essen...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tabriz University of Medical Sciences (TUOMS Publishing Group)
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905592/ https://www.ncbi.nlm.nih.gov/pubmed/35411300 http://dx.doi.org/10.34172/bi.2021.39 |
_version_ | 1784665220657971200 |
---|---|
author | Shakouri, Amir Kahroba, Houman Hamishekar, Hamed Abdolalizadeh, Jalal |
author_facet | Shakouri, Amir Kahroba, Houman Hamishekar, Hamed Abdolalizadeh, Jalal |
author_sort | Shakouri, Amir |
collection | PubMed |
description | [Image: see text] Introduction: Breast cancer is the most serious cause of women’s death throughout the world. Using nanocarrier vehicles to the exact site of cancer upgrades the therapeutic efficiency of the drugs. Capsulation of active proteins in the vesicular liposomes’ hydrophilic core is essential to develop a therapeutic protein carrier system. We aimed to encapsulate the medicinal leech saliva extract (LSE) and assess the inhibition of angiogenesis of breast cancer cells by targeting vascular endothelial growth factor A (VEGFA). Methods: In this research, enhanced formulation of liposomal protein was determined by zeta potential analysis, droplet size, drug release assay, and transmission electron microscopy (TEM). Furthermore, a cytotoxicity assay of liposomal LSE was performed to determine the cytotoxic activity of components. For assessing the expression of VEGFA, P53, and hypoxia-inducible factor subunit alpha (HIF1a) genes, Real-Time PCR was applied. Results: Nano liposome was chosen as an enhanced formulation due to its much smaller size (46.23 nm). Liposomal LSE had more practical actions on the MCF-7 cells. As noticed by DAPI staining, apoptosis was extensively greater in treated MCF-7 cells. Wound healing assay demonstrated that MCF-7 cells could not sustain growth at the presence of liposomal LSE and expression of the VEGFA gene was declined in treated cells. Downregulation of VEGFA was evaluated with western blotting technique. Conclusion: It can be concluded that our investigation of the tests confirmed the fact that nano liposomal LSE is a novel promising formulation for anticancer drugs and can significantly improve the penetration of protein drugs to cancer cells. |
format | Online Article Text |
id | pubmed-8905592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Tabriz University of Medical Sciences (TUOMS Publishing Group) |
record_format | MEDLINE/PubMed |
spelling | pubmed-89055922022-04-10 Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7) Shakouri, Amir Kahroba, Houman Hamishekar, Hamed Abdolalizadeh, Jalal Bioimpacts Original Research [Image: see text] Introduction: Breast cancer is the most serious cause of women’s death throughout the world. Using nanocarrier vehicles to the exact site of cancer upgrades the therapeutic efficiency of the drugs. Capsulation of active proteins in the vesicular liposomes’ hydrophilic core is essential to develop a therapeutic protein carrier system. We aimed to encapsulate the medicinal leech saliva extract (LSE) and assess the inhibition of angiogenesis of breast cancer cells by targeting vascular endothelial growth factor A (VEGFA). Methods: In this research, enhanced formulation of liposomal protein was determined by zeta potential analysis, droplet size, drug release assay, and transmission electron microscopy (TEM). Furthermore, a cytotoxicity assay of liposomal LSE was performed to determine the cytotoxic activity of components. For assessing the expression of VEGFA, P53, and hypoxia-inducible factor subunit alpha (HIF1a) genes, Real-Time PCR was applied. Results: Nano liposome was chosen as an enhanced formulation due to its much smaller size (46.23 nm). Liposomal LSE had more practical actions on the MCF-7 cells. As noticed by DAPI staining, apoptosis was extensively greater in treated MCF-7 cells. Wound healing assay demonstrated that MCF-7 cells could not sustain growth at the presence of liposomal LSE and expression of the VEGFA gene was declined in treated cells. Downregulation of VEGFA was evaluated with western blotting technique. Conclusion: It can be concluded that our investigation of the tests confirmed the fact that nano liposomal LSE is a novel promising formulation for anticancer drugs and can significantly improve the penetration of protein drugs to cancer cells. Tabriz University of Medical Sciences (TUOMS Publishing Group) 2022 2021-08-09 /pmc/articles/PMC8905592/ /pubmed/35411300 http://dx.doi.org/10.34172/bi.2021.39 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc/4.0/ This work is published by BioImpacts as an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ). Non-commercial uses of the work are permitted, provided the original work is properly cited. |
spellingShingle | Original Research Shakouri, Amir Kahroba, Houman Hamishekar, Hamed Abdolalizadeh, Jalal Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7) |
title |
Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7)
|
title_full |
Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7)
|
title_fullStr |
Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7)
|
title_full_unstemmed |
Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7)
|
title_short |
Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7)
|
title_sort | nanoencapsulation of hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting vegfa in the breast cancer cell line (mcf-7) |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905592/ https://www.ncbi.nlm.nih.gov/pubmed/35411300 http://dx.doi.org/10.34172/bi.2021.39 |
work_keys_str_mv | AT shakouriamir nanoencapsulationofhirudomedicinalisproteinsinliposomesasananocarrierforinhibitingangiogenesisthroughtargetingvegfainthebreastcancercelllinemcf7 AT kahrobahouman nanoencapsulationofhirudomedicinalisproteinsinliposomesasananocarrierforinhibitingangiogenesisthroughtargetingvegfainthebreastcancercelllinemcf7 AT hamishekarhamed nanoencapsulationofhirudomedicinalisproteinsinliposomesasananocarrierforinhibitingangiogenesisthroughtargetingvegfainthebreastcancercelllinemcf7 AT abdolalizadehjalal nanoencapsulationofhirudomedicinalisproteinsinliposomesasananocarrierforinhibitingangiogenesisthroughtargetingvegfainthebreastcancercelllinemcf7 |